The posaconazole pharmacokinetic in critically ill patients will be studied in a prospective, non-interventional, monocentric observational trial.
The posaconazole pharmacokinetic in critically ill patients will be studied in a prospective, non-interventional, monocentric observational trial. Plasma specimens will be retrieved on consecutive days (max. 7 days) in order to measure posaconazole levels during the treatment episode.
Study Type
OBSERVATIONAL
Enrollment
10
Therapeutic Drug Monitoring is performed by measuring posaconazole concentrations in serum on seven consecutive days (anticipated).
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
Posaconazole Drug Exposure
Measurement of posaconazole concentration in serum
Time frame: seven days from therapystart
population-pharmacokinetic analysis 1
Analysis of Peak Plasma Concentration (Cmax) for posaconazole in the given cohort.
Time frame: 12 months after close out
population-pharmacokinetic analysis 2
Analysis of Area under the plasma concentration versus time curve (AUC) for posaconazole in the given cohort.
Time frame: 12 months after close out
Evaluation of probability of target attainment of posaconazole
Analysis of Monte-Carlo-Simulations in order to asses novel dosing regimens for posaconazole.
Time frame: 12 months after close out
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.